Chadds Fords, PA, June 5 2020: MOBILion Systems, Inc. is showcasing its first ion mobility separations product to the biopharma drug development and academic research markets, with data from its first beta users, during the American Society for Mass Spectrometry’s (ASMS) virtual conference.
In this post, we decided to highlight eleven entrepreneurial women, leading the way in applying advanced computational technologies, such as machine learning (ML), deep learning (DL), and other artificial intelligence (AI) components, for tackling some of the hardest challenges of science -- in drug discovery and healthcare. This list is composed in alphabetical order.
Synonymous codon substitutions affect the mRNA coding sequence, but the encoded amino acid sequence remains unchanged. Therefore, ostensibly these substitutions do not affect the phenotype and are often ignored in the study of human genetic variation. However, a variety of studies have shown that protein levels, translational accuracy, secretory efficiency, final folding structure and post-translational modifications are regulated by multiple mechanisms.
Synonymous codon action has gradually emerged, and the precise mechanism has yet to be discovered. Studies on the interference of synonymous codon substitution on the co-translational folding mechanism often lack in vivo evidence, and usually, rare synonymous codons tend to translate more slowly than ordinary synonymous codons. In addition, rare synonymous codons tend to appear in clusters, many of which are preserved during evolutionary history. The folding rates of many protein secondary and tertiary structures are similar to their synthesis rates, and subtle changes in elongation may also alter the folding mechanism.
Theoretically, synonymous rare codon substitutions reduce translational elongation and can provide more time for the N-terminal portion of the nascent protein to form a stable tertiary structure before the C-terminal portion emerges from the ribosome exit tunnel. Is the extra time good or bad for efficient folding? Cells contain a chaperone network to facilitate protein folding. It is unclear whether altered elongation and co-translational folding mechanisms of synonymous codons interfere with chaperone function.
Recently, in research published in the Immunity, researchers from University College London in the United Kingdom revealed that a special type of immune cells can be activated to kill cancerous cells through research on mice. Related research may give hope for the development of new types of anticancer therapy.
The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some cancers. Cell technologies, as a growing sub-field in the immunotherapy landscape, have progressed considerably and now represent a $26 billion financial opportunity by 2030, according to a report by Roots Analysis.